Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Copyright © 2023 Massachusetts Medical Society..
BACKGROUND: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment duration according to measurable residual disease (MRD) is more effective than fludarabine-cyclophosphamide-rituximab (FCR) is unclear.
METHODS: In this phase 3, multicenter, randomized, controlled, open-label platform trial involving patients with untreated CLL, we compared ibrutinib-venetoclax and ibrutinib monotherapy with FCR. In the ibrutinib-venetoclax group, after 2 months of ibrutinib, venetoclax was added for up to 6 years of therapy. The duration of ibrutinib-venetoclax therapy was defined by MRD assessed in peripheral blood and bone marrow and was double the time taken to achieve undetectable MRD. The primary end point was progression-free survival in the ibrutinib-venetoclax group as compared with the FCR group, results that are reported here. Key secondary end points were overall survival, response, MRD, and safety.
RESULTS: A total of 523 patients were randomly assigned to the ibrutinib-venetoclax group or the FCR group. At a median of 43.7 months, disease progression or death had occurred in 12 patients in the ibrutinib-venetoclax group and 75 patients in the FCR group (hazard ratio, 0.13; 95% confidence interval [CI], 0.07 to 0.24; P<0.001). Death occurred in 9 patients in the ibrutinib-venetoclax group and 25 patients in the FCR group (hazard ratio, 0.31; 95% CI, 0.15 to 0.67). At 3 years, 58.0% of the patients in the ibrutinib-venetoclax group had stopped therapy owing to undetectable MRD. After 5 years of ibrutinib-venetoclax therapy, 65.9% of the patients had undetectable MRD in the bone marrow and 92.7% had undetectable MRD in the peripheral blood. The risk of infection was similar in the ibrutinib-venetoclax group and the FCR group. The percentage of patients with cardiac serious adverse events was higher in the ibrutinib-venetoclax group than in the FCR group (10.7% vs. 0.4%).
CONCLUSIONS: MRD-directed ibrutinib-venetoclax improved progression-free survival as compared with FCR, and results for overall survival also favored ibrutinib-venetoclax. (Funded by Cancer Research UK and others; FLAIR ISRCTN Registry number, ISRCTN01844152; EudraCT number, 2013-001944-76.).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:390 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 390(2024), 4 vom: 25. Jan., Seite 326-337 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Munir, Talha [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.01.2024 Date Revised 20.03.2024 published: Print-Electronic ISRCTN: ISRCTN01844152 EudraCT: 2013-001944-76 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2310063 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365693197 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365693197 | ||
| 003 | DE-627 | ||
| 005 | 20240320233747.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2310063 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM365693197 | ||
| 035 | |a (NLM)38078508 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Munir, Talha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2024 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ISRCTN: ISRCTN01844152 | ||
| 500 | |a EudraCT: 2013-001944-76 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment duration according to measurable residual disease (MRD) is more effective than fludarabine-cyclophosphamide-rituximab (FCR) is unclear | ||
| 520 | |a METHODS: In this phase 3, multicenter, randomized, controlled, open-label platform trial involving patients with untreated CLL, we compared ibrutinib-venetoclax and ibrutinib monotherapy with FCR. In the ibrutinib-venetoclax group, after 2 months of ibrutinib, venetoclax was added for up to 6 years of therapy. The duration of ibrutinib-venetoclax therapy was defined by MRD assessed in peripheral blood and bone marrow and was double the time taken to achieve undetectable MRD. The primary end point was progression-free survival in the ibrutinib-venetoclax group as compared with the FCR group, results that are reported here. Key secondary end points were overall survival, response, MRD, and safety | ||
| 520 | |a RESULTS: A total of 523 patients were randomly assigned to the ibrutinib-venetoclax group or the FCR group. At a median of 43.7 months, disease progression or death had occurred in 12 patients in the ibrutinib-venetoclax group and 75 patients in the FCR group (hazard ratio, 0.13; 95% confidence interval [CI], 0.07 to 0.24; P<0.001). Death occurred in 9 patients in the ibrutinib-venetoclax group and 25 patients in the FCR group (hazard ratio, 0.31; 95% CI, 0.15 to 0.67). At 3 years, 58.0% of the patients in the ibrutinib-venetoclax group had stopped therapy owing to undetectable MRD. After 5 years of ibrutinib-venetoclax therapy, 65.9% of the patients had undetectable MRD in the bone marrow and 92.7% had undetectable MRD in the peripheral blood. The risk of infection was similar in the ibrutinib-venetoclax group and the FCR group. The percentage of patients with cardiac serious adverse events was higher in the ibrutinib-venetoclax group than in the FCR group (10.7% vs. 0.4%) | ||
| 520 | |a CONCLUSIONS: MRD-directed ibrutinib-venetoclax improved progression-free survival as compared with FCR, and results for overall survival also favored ibrutinib-venetoclax. (Funded by Cancer Research UK and others; FLAIR ISRCTN Registry number, ISRCTN01844152; EudraCT number, 2013-001944-76.) | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Bridged Bicyclo Compounds, Heterocyclic |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a fludarabine |2 NLM | |
| 650 | 7 | |a P2K93U8740 |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a venetoclax |2 NLM | |
| 650 | 7 | |a N54AIC43PW |2 NLM | |
| 650 | 7 | |a Vidarabine |2 NLM | |
| 650 | 7 | |a FA2DM6879K |2 NLM | |
| 700 | 1 | |a Cairns, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Bloor, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Allsup, David |e verfasserin |4 aut | |
| 700 | 1 | |a Cwynarski, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Pettitt, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Paneesha, Shankara |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Christopher P |e verfasserin |4 aut | |
| 700 | 1 | |a Eyre, Toby A |e verfasserin |4 aut | |
| 700 | 1 | |a Forconi, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Elmusharaf, Nagah |e verfasserin |4 aut | |
| 700 | 1 | |a Kennedy, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Gribben, John |e verfasserin |4 aut | |
| 700 | 1 | |a Pemberton, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Sheehy, Oonagh |e verfasserin |4 aut | |
| 700 | 1 | |a Preston, Gavin |e verfasserin |4 aut | |
| 700 | 1 | |a Schuh, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Walewska, Renata |e verfasserin |4 aut | |
| 700 | 1 | |a Duley, Lelia |e verfasserin |4 aut | |
| 700 | 1 | |a Howard, Dena |e verfasserin |4 aut | |
| 700 | 1 | |a Hockaday, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Greatorex, Natasha |e verfasserin |4 aut | |
| 700 | 1 | |a Girvan, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, Sue |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Julia M |e verfasserin |4 aut | |
| 700 | 1 | |a Webster, Nichola |e verfasserin |4 aut | |
| 700 | 1 | |a Dalal, Surita |e verfasserin |4 aut | |
| 700 | 1 | |a de Tute, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Rawstron, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Patten, Piers E M |e verfasserin |4 aut | |
| 700 | 1 | |a Hillmen, Peter |e verfasserin |4 aut | |
| 700 | 0 | |a National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup |e verfasserin |4 aut | |
| 700 | 1 | |a Cwynarksi, Kate |e investigator |4 oth | |
| 700 | 1 | |a Pettitt, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Bloor, Adrian |e investigator |4 oth | |
| 700 | 1 | |a Munir, Talha |e investigator |4 oth | |
| 700 | 1 | |a Allsup, David |e investigator |4 oth | |
| 700 | 1 | |a Eyre, Toby |e investigator |4 oth | |
| 700 | 1 | |a Patten, Piers |e investigator |4 oth | |
| 700 | 1 | |a Fox, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Forconi, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Kennedy, Ben |e investigator |4 oth | |
| 700 | 1 | |a Elmusharaf, Nagah |e investigator |4 oth | |
| 700 | 1 | |a Pemberton, Nicholas |e investigator |4 oth | |
| 700 | 1 | |a Sheehy, Oonagh |e investigator |4 oth | |
| 700 | 1 | |a Macheta, Marian |e investigator |4 oth | |
| 700 | 1 | |a Gribben, John |e investigator |4 oth | |
| 700 | 1 | |a Preston, Gavin |e investigator |4 oth | |
| 700 | 1 | |a Jasani, Parag |e investigator |4 oth | |
| 700 | 1 | |a Paneesha, Shankara |e investigator |4 oth | |
| 700 | 1 | |a Morley, Nick |e investigator |4 oth | |
| 700 | 1 | |a Phillips, Neil |e investigator |4 oth | |
| 700 | 1 | |a Knechtli, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Mohan, Mahalakshmi |e investigator |4 oth | |
| 700 | 1 | |a Todd, Anthony |e investigator |4 oth | |
| 700 | 1 | |a Neilson, Jeff |e investigator |4 oth | |
| 700 | 1 | |a Mohite, Unmesh |e investigator |4 oth | |
| 700 | 1 | |a Naeem, Abida |e investigator |4 oth | |
| 700 | 1 | |a Kaczmarek, Pawel |e investigator |4 oth | |
| 700 | 1 | |a Chalmers, Isobel |e investigator |4 oth | |
| 700 | 1 | |a Dungarwalla, Moez |e investigator |4 oth | |
| 700 | 1 | |a Nagumantry, Sateesh |e investigator |4 oth | |
| 700 | 1 | |a Sidra, Gamal |e investigator |4 oth | |
| 700 | 1 | |a Belsham, Edward |e investigator |4 oth | |
| 700 | 1 | |a Furtado, Michelle |e investigator |4 oth | |
| 700 | 1 | |a Zhelyazkova, Antonina |e investigator |4 oth | |
| 700 | 1 | |a Eden, Dewi |e investigator |4 oth | |
| 700 | 1 | |a Narat, Santosh |e investigator |4 oth | |
| 700 | 1 | |a Makkuni, Sudhakaran |e investigator |4 oth | |
| 700 | 1 | |a Rafferty, Mark |e investigator |4 oth | |
| 700 | 1 | |a Chavda, Nikesh |e investigator |4 oth | |
| 700 | 1 | |a Hall, Claire |e investigator |4 oth | |
| 700 | 1 | |a Parry-Jones, Nilima |e investigator |4 oth | |
| 700 | 1 | |a McCaig, Alison |e investigator |4 oth | |
| 700 | 1 | |a Duncan, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Willis, Fenella |e investigator |4 oth | |
| 700 | 1 | |a Eagleton, Helen |e investigator |4 oth | |
| 700 | 1 | |a Singh, Vikram |e investigator |4 oth | |
| 700 | 1 | |a Broom, Angus |e investigator |4 oth | |
| 700 | 1 | |a Watson, David |e investigator |4 oth | |
| 700 | 1 | |a Follows, George |e investigator |4 oth | |
| 700 | 1 | |a McCulloch, Rory |e investigator |4 oth | |
| 700 | 1 | |a Cheung, Betty |e investigator |4 oth | |
| 700 | 1 | |a Maddox, Jamie |e investigator |4 oth | |
| 700 | 1 | |a Jones, Steve |e investigator |4 oth | |
| 700 | 1 | |a Austen, Belinda |e investigator |4 oth | |
| 700 | 1 | |a Greaves, Paul |e investigator |4 oth | |
| 700 | 1 | |a Ruparellia, Meghna |e investigator |4 oth | |
| 700 | 1 | |a Watt, Simon |e investigator |4 oth | |
| 700 | 1 | |a Whittle, Annika |e investigator |4 oth | |
| 700 | 1 | |a Pratt, Guy |e investigator |4 oth | |
| 700 | 1 | |a Walewska, Renata |e investigator |4 oth | |
| 700 | 1 | |a Grey-Davies, Elisabeth |e investigator |4 oth | |
| 700 | 1 | |a Turner, Deborah |e investigator |4 oth | |
| 700 | 1 | |a Al-Sader, Hassen |e investigator |4 oth | |
| 700 | 1 | |a Elder, Patrick |e investigator |4 oth | |
| 700 | 1 | |a Rothwell, Kate |e investigator |4 oth | |
| 700 | 1 | |a Tueger, Salaheddin |e investigator |4 oth | |
| 700 | 1 | |a Nicholson, Fiona |e investigator |4 oth | |
| 700 | 1 | |a Hutchinson, Claire |e investigator |4 oth | |
| 700 | 1 | |a De Lord, Corinne |e investigator |4 oth | |
| 700 | 1 | |a Heartin, Earnest |e investigator |4 oth | |
| 700 | 1 | |a Marks, Sasha |e investigator |4 oth | |
| 700 | 1 | |a Kwan, Mark |e investigator |4 oth | |
| 700 | 1 | |a Burns, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Mitchell, Lindsay |e investigator |4 oth | |
| 700 | 1 | |a Jayaprakash, Ram |e investigator |4 oth | |
| 700 | 1 | |a Marshall, Scott |e investigator |4 oth | |
| 700 | 1 | |a Jackson, Helen |e investigator |4 oth | |
| 700 | 1 | |a Howarth, David |e investigator |4 oth | |
| 700 | 1 | |a Iyengar, Sunil |e investigator |4 oth | |
| 700 | 1 | |a Hasan, Yasmin |e investigator |4 oth | |
| 700 | 1 | |a Nicolle, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Davidson, Kerri |e investigator |4 oth | |
| 700 | 1 | |a Chew, Anastasia |e investigator |4 oth | |
| 700 | 1 | |a Todd, Sophie |e investigator |4 oth | |
| 700 | 1 | |a Morris, Anna |e investigator |4 oth | |
| 700 | 1 | |a Muddana, Jhansi |e investigator |4 oth | |
| 700 | 1 | |a Goddard, Kathryn |e investigator |4 oth | |
| 700 | 1 | |a Arnold, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Ravenscroft, Sonya |e investigator |4 oth | |
| 700 | 1 | |a Milnthorpe, James |e investigator |4 oth | |
| 700 | 1 | |a Ponnambath, Afzal |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 390(2024), 4 vom: 25. Jan., Seite 326-337 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:390 |g year:2024 |g number:4 |g day:25 |g month:01 |g pages:326-337 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2310063 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 390 |j 2024 |e 4 |b 25 |c 01 |h 326-337 | ||